



SWIXX ENTERS INTO A STRATEGIC MULTIREGIONAL DISTRIBUTION PARTNERSHIP WITH BRIDGEBIO

Baar, Switzerland, March 30th, 2026 – Swixx BioPharma AG, a global commercial platform dedicated to unlocking access to innovative medicines worldwide, is pleased to announce the signing of an exclusive Distribution Agreement with BridgeBio. Under the terms of the agreement, Swixx will be responsible for the distribution and commercialization of acoramidis across 12 countries in the regions of Latin America and MENA.

Where approved, acoramidis is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.¹ ATTR-CM is a progressive, debilitating disease that diminishes quality of life, causes recurrent hospitalization, and leads to premature death.²⁻⁴ Acoramidis is not currently approved in the countries covered by this agreement, and any commercialization will be subject to applicable regulatory approvals and local regulations.

Swixx is proud to have been selected by BridgeBio as a partner in these two regions, reflecting a shared commitment to bringing meaningful treatments to patients with ATTR-CM who currently have limited options.

 **Pascal Forget, Regional General Manager Latam, commented:** “For people living with ATTR-CM, time and access matter. Through this partnership with BridgeBio, our teams across Latin America will focus on making acoramidis available where it is most needed, including large markets such as Brazil and Mexico. Our priority is simple: to help ensure that patients can reach the right treatment as early as possible, working closely with BridgeBio, healthcare systems and all local partners.”

 **Manar Al Nahar, Regional General Manager MENAT, added:** “In the MENA region, many patients with rare and complex heart conditions still face delays in diagnosis and treatment. This partnership is about changing that reality. Together with BridgeBio, and in close collaboration with healthcare professionals, authorities and other local stakeholders, we will work to bring acoramidis closer to patients so that people can timely receive it.”



About Swixx Group

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With presence in more than 50 countries, 2,100 employees and sales which exceeded 1.4 billion Euros in 2025, the Group is one of the fastest-growing independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and CNS therapy area talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.



Swixx Group investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Stuart Swanson, Head of Corporate Development
bd.info@swixxbiopharma.com

Swixx Group media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

References:

1. FDA, Full Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf. Last accessed March 2026. 2. Lane T, et al. Circulation. 2019;140(1):16-26. 3. Rintell D, et al. Orphanet J Rare Dis. 2021;16(1):70. 4. Nativi-Nicolau J, et al. ESC Heart Fail. 2021;8(5):3875-3884.

